BridgeMD
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA
EU CTIS ID: 2023-507883-38-00
What this study is testing
To evaluate the efficacy of baricitinib in children with Systemic juvenile idiopathic arthritis (sJIA)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) with onset before the age of 16 years.
- Participants must have arthritis in a joint and fever lasting 2 weeks, with daily fever for 3 days, and at least 1 of the following: Evanescent erythematous rash, generalized lymph node enlargement, enlarged liver/spleen, serositis.
- Participants must have at least 2 active joints.
You likely can't join if
- Participants must not have polyarticular JIA, extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis.
- Participants must not have persistent oligoarticular arthritis.
- Participants must not have any autoimmune inflammatory condition other than JIA.
- Participants must not have active anterior uveitis.
- Participants must not have active fibromyalgia or other chronic pain conditions.
- Participants must not have an infection.
The study team makes the final eligibility decision.
Where it's taking place
- Russian Federation
- Brazil
- Argentina
- United Kingdom
- Israel
- Turkey
- Japan
- India
- Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Russian Federation; Brazil; Argentina; United Kingdom; Israel; Turkey and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.